Biotech drug developer Repligen Corp. said Sept. 10 ImClone Systems Inc. has agreed to pay $65 million to Repligen and co-plaintiff Massachusetts Institute of Technology as part of a patent infringement case settlement. The case began in May 2004, when Repligen and MIT filed a patent infringement suit against ImClone related to the manufacture and sale of the drug Erbitux. The patent in question is held by MIT and exclusively licensed to Repligen.
September 10, 2007 at 12:00 AM
1 minute read
The original version of this story was published on Law.Com
Biotech drug developer Repligen Corp. said Sept. 10 ImClone Systems Inc. has agreed to pay $65 million to Repligen and co-plaintiff Massachusetts Institute of Technology as part of a patent infringement case settlement.
The case began in May 2004, when Repligen and MIT filed a patent infringement suit against ImClone related to the manufacture and sale of the drug Erbitux. The patent in question is held by MIT and exclusively licensed to Repligen.
Presented by BigVoodoo
Law firms & in-house legal departments with a presence in the middle east celebrate outstanding achievement within the profession.
The premier educational and networking event for employee benefits brokers and agents.
The Legal Intelligencer honors lawyers leaving a mark on the legal community in Pennsylvania and Delaware.
Atlanta s John Marshall Law School is seeking to hire one or more full-time, visiting Legal WritingInstructors to teach Legal Research, Anal...
Lower Manhattan firm seeks a premises liability litigator (i.e., depositions, SJ motions, and/or trials) with at least 3-6 years of experien...
Evergreen Trading is a media investment firm headquartered in NYC. We help brands achieve their goals by leveraging their unwanted assets to...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
